Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ferrandina

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Gynecologic Oncology|July 25, 2020
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control studyD Lorusso, C Marchetti, C Conte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinomaS Fiumicino, A Ercoli, G Ferrandina, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantationA Fattorossi, A Battaglia, L Pierelli, et al.
British Journal of Cancer|January 1, 1997
Prognostic significance of ras/p21 alterations in human ovarian cancerG Scambia, V Masciullo, P Benedetti Panici, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2025
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 studyG Candotti, A Bergamini, M Perrone, et al.
Gynecologic Oncology|April 26, 2002
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancerG Ferrandina, F O Ranelletti, L Lauriola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patientsG Ferrandina, L Lauriola, G F Zannoni, et al.
British Journal of Cancer|November 26, 1999
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerG Ferrandina, A Fagotti, M G Salerno, et al.
British Journal of Cancer|December 1, 1990
Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsG Scambia, F O Ranelletti, P B Panici, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 14, 2011
Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective studyA C Testa, M Ludovisi, F Mascilini, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology|July 25, 2020
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control studyD Lorusso, C Marchetti, C Conte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinomaS Fiumicino, A Ercoli, G Ferrandina, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantationA Fattorossi, A Battaglia, L Pierelli, et al.
British Journal of Cancer|January 1, 1997
Prognostic significance of ras/p21 alterations in human ovarian cancerG Scambia, V Masciullo, P Benedetti Panici, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2025
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 studyG Candotti, A Bergamini, M Perrone, et al.
Gynecologic Oncology|April 26, 2002
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancerG Ferrandina, F O Ranelletti, L Lauriola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patientsG Ferrandina, L Lauriola, G F Zannoni, et al.
British Journal of Cancer|November 26, 1999
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerG Ferrandina, A Fagotti, M G Salerno, et al.
British Journal of Cancer|December 1, 1990
Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsG Scambia, F O Ranelletti, P B Panici, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 14, 2011
Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective studyA C Testa, M Ludovisi, F Mascilini, et al.
Pageof 18